- Home
- ATRA vs ABOS Comparison
ATRA vs ABOS Comparison
Compare ATRA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- ABOS
- Stock Information
- Founded
- ATRA 2012
- ABOS 1996
- Country
- ATRA United States
- ABOS United States
- Employees
- ATRA N/A
- ABOS N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- ABOS Health Care
- Exchange
- ATRA Nasdaq
- ABOS Nasdaq
- Market Cap
- ATRA 97.0M
- ABOS 109.6M
- IPO Year
- ATRA 2014
- ABOS 2021
- Fundamental
- Price
- ATRA $13.04
- ABOS $1.55
- Analyst Decision
- ATRA Strong Buy
- ABOS Strong Buy
- Analyst Count
- ATRA 3
- ABOS 3
- Target Price
- ATRA $21.00
- ABOS $8.00
- AVG Volume (30 Days)
- ATRA 59.0K
- ABOS 275.1K
- Earning Date
- ATRA 11-12-2025
- ABOS 11-12-2025
- Dividend Yield
- ATRA N/A
- ABOS N/A
- EPS Growth
- ATRA N/A
- ABOS N/A
- EPS
- ATRA 1.97
- ABOS N/A
- Revenue
- ATRA $151,930,000.00
- ABOS N/A
- Revenue This Year
- ATRA N/A
- ABOS N/A
- Revenue Next Year
- ATRA N/A
- ABOS N/A
- P/E Ratio
- ATRA $6.70
- ABOS N/A
- Revenue Growth
- ATRA 51.27
- ABOS N/A
- 52 Week Low
- ATRA $5.01
- ABOS $0.86
- 52 Week High
- ATRA $18.71
- ABOS $2.66
- Technical
- Relative Strength Index (RSI)
- ATRA 47.86
- ABOS 35.12
- Support Level
- ATRA $11.21
- ABOS $1.74
- Resistance Level
- ATRA $14.28
- ABOS $2.04
- Average True Range (ATR)
- ATRA 1.33
- ABOS 0.16
- MACD
- ATRA 0.01
- ABOS -0.07
- Stochastic Oscillator
- ATRA 52.74
- ABOS 9.20
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.